Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Technology (Egg-based, and Cell culture), Age Group (Pediatric, and Adult), and Route of Administration (Injection, and Nasal Spray), and Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Influenza Vaccine Market is estimated to be valued at USD 7.32 Billion in 2022 and is poised to grow at a significant CAGR of 6.5% over 2023-2029. The market refers to the industry that encompasses the production, distribution, and sales of vaccines used for preventing influenza, commonly known as the flu. Influenza is a contagious respiratory illness caused by influenza viruses and can lead to severe complications and even death. Vaccination is a crucial preventive measure in reducing the incidence and severity of influenza infections. The influenza vaccine market is diverse, with various players including pharmaceutical companies, biotechnology firms, and government agencies involved in its development and distribution. These entities collaborate to develop and manufacture different types of influenza vaccines, such as trivalent, quadrivalent, and high-dose vaccines, targeting specific strains of the virus. Several trends shape the global influenza vaccine market. Increased emphasis on improving the effectiveness and coverage of influenza vaccines, especially for high-risk populations like the elderly and individuals with chronic illnesses. This has led to the development of more advanced vaccine technologies and formulations. Additionally, technological advancements in vaccine delivery, such as the development of intranasal and microneedle-based vaccines, are gaining attention for their potential to enhance vaccine coverage and ease of administration. The global influenza vaccine market dynamics are driven by the need to prevent and control influenza infections. It is characterized by diverse players, ongoing technological advancements, and increasing demand for improved vaccine effectiveness and coverage. The market is expected to continue evolving to address emerging challenges and provide better protection against influenza viruses.

Influenza Vaccine Market Key Developments:

In February 2023 Sanofi Pasteur and GlaxoSmithKline (GSK) announced a collaboration to develop and commercialize an influenza vaccine that combines their respective quadrivalent live attenuated influenza vaccine (LAIV) platforms. The new vaccine is expected to be available in the United States in the 2023-2024 influenza season.

In January 2023 Seqirus and the Bill & Melinda Gates Foundation announced a collaboration to develop and deliver influenza vaccines to children in low- and middle-income countries. The collaboration will focus on developing new and improved influenza vaccines that are more affordable and accessible for children in these countries.

Global Influenza Vaccine Market Summary

Study Period

2023-29

Base Year

2022

CAGR

6.5%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Influenza Vaccine Market Dynamics

Increasing awareness about the importance of influenza vaccination has led to a higher demand for vaccines around the globe. People are now more informed about the benefits of getting vaccinated against the flu, leading to increased uptake of vaccines. Governments and healthcare organizations have played a significant role in promoting vaccination campaigns, emphasizing the prevention of seasonal outbreaks and potential pandemics. This heightened awareness has resulted in a surge in demand for the influenza vaccines market worldwide, as individuals recognize the value of protecting themselves and others from influenza infections.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Global Influenza Vaccine Market Segmentation

By Vaccine Type
  • Quadrivalent
  • Trivalent
By Type
  • Seasonal
  • Pandemic
By Technology
  • Egg-based
  • Cell-based
By Route of Administration
  • Injection
  • Nasal Spray
By Age Group
  • Pediatric
  • Adult
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

Influenza, commonly known as flu, is a contagious respiratory infection or illness caused by influenza viruses. The influenza vaccine protects a person from getting the flu.

The major factor for the growth of the Influenza Vaccine Market is a high prevalence of influenza, an increase in government focuses on immunization programs, emerging vaccines, and technological progress in vaccine administration.

Astrazeneca Plc (Astrazeneca), Biodiem, Csl Limited (Seqirus GmbH), Emergent Biosolutions, F. Hoffmann-La Roche Ltd., Gamma Vaccines Pty Ltd., Glaxosmithkline Plc.

 

 

  • Astrazeneca Plc (Astrazeneca)
  • Biodiem
  • Csl Limited (Seqirus GmbH)
  • Emergent Biosolutions
  • Hoffmann-La Roche Ltd.
  • Gamma Vaccines Pty Ltd.
  • Glaxosmithkline Plc.
  • Merck & Co., Inc. (Merck Sharp & Dohme Corp.)
  • Novartis Ag
  • Pfizer, Inc.
  • Sanofi
  • Sinovac Biotech Ltd.